DK1626736T3 - C1-inhibitor med kort halveringstid til midlertidig behandling - Google Patents

C1-inhibitor med kort halveringstid til midlertidig behandling Download PDF

Info

Publication number
DK1626736T3
DK1626736T3 DK04748575.0T DK04748575T DK1626736T3 DK 1626736 T3 DK1626736 T3 DK 1626736T3 DK 04748575 T DK04748575 T DK 04748575T DK 1626736 T3 DK1626736 T3 DK 1626736T3
Authority
DK
Denmark
Prior art keywords
inhibitor
life
short half
temporary treatment
temporary
Prior art date
Application number
DK04748575.0T
Other languages
English (en)
Inventor
Johannes Henricus Nuijens
Original Assignee
Pharming Intellectual Property B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharming Intellectual Property B V filed Critical Pharming Intellectual Property B V
Application granted granted Critical
Publication of DK1626736T3 publication Critical patent/DK1626736T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK04748575.0T 2003-05-16 2004-05-14 C1-inhibitor med kort halveringstid til midlertidig behandling DK1626736T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03076466 2003-05-16
PCT/NL2004/000330 WO2004100982A1 (en) 2003-05-16 2004-05-14 C1 inhibitor with short half-life for transient treatment

Publications (1)

Publication Number Publication Date
DK1626736T3 true DK1626736T3 (da) 2020-09-28

Family

ID=33442800

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04748575.0T DK1626736T3 (da) 2003-05-16 2004-05-14 C1-inhibitor med kort halveringstid til midlertidig behandling

Country Status (15)

Country Link
US (2) US7544853B2 (da)
EP (1) EP1626736B1 (da)
JP (1) JP2007500741A (da)
CN (1) CN100431604C (da)
AU (1) AU2004238170B2 (da)
CA (1) CA2525522A1 (da)
CY (1) CY1123601T1 (da)
DK (1) DK1626736T3 (da)
ES (1) ES2830499T3 (da)
HU (1) HUE052154T2 (da)
NZ (1) NZ543646A (da)
PL (1) PL1626736T3 (da)
PT (1) PT1626736T (da)
SI (1) SI1626736T1 (da)
WO (1) WO2004100982A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003301332B2 (en) * 2002-10-17 2008-06-12 Pharming Intellectual Property B.V. Protein modification
US7544853B2 (en) * 2003-05-16 2009-06-09 Pharming Intellectual Property B.V. C1 inhibitor with short half-life transient treatment
CN101102819A (zh) 2004-12-23 2008-01-09 Csl百灵有限公司 血栓的形成和/或稳定化的预防
US8071532B2 (en) * 2005-12-21 2011-12-06 Pharming Intellectual Property B.V. Use of C1 inhibitor for the prevention of ischemia-reperfusion injury
PT2380587T (pt) * 2005-12-21 2018-01-19 Pharming Intellectual Property B V Resumo
LT3028716T (lt) * 2006-10-10 2020-12-10 Regenesance B.V. Komplemento slopinimas nervų regeneracijos pagerinimui
CN103415301A (zh) 2011-03-09 2013-11-27 德国杰特贝林生物制品有限公司 用于与包括与人造表面接触的医疗操作一起施用的fxii抑制剂
EP2497489A1 (en) 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
US20160058850A1 (en) * 2012-11-13 2016-03-03 Biogenius Llc Compositions and methods for treating inflammatory diseases of infectious and non-infectious origin
DK2961422T3 (da) * 2013-02-28 2017-01-16 Csl Behring Gmbh Terapeutisk middel mod fostervands-emboli
WO2014135694A1 (en) 2013-03-08 2014-09-12 Csl Behring Ag Treatment and prevention of remote ischemia-reperfusion injury
ME02865B (me) 2013-03-15 2018-04-20 Shire Viropharma Inc C1-inh kompozicije za upotrebu u prevenciji i liječenju naslednog angioedema (hae)
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US20150104445A1 (en) * 2013-10-10 2015-04-16 Viropharma Holdings Limited Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein
CA2940670A1 (en) * 2014-02-28 2015-09-03 Santarus, Inc. Treatment of hereditary angioedema with c1 inhibitor
WO2019166572A1 (en) 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
BR112020017626A2 (pt) * 2018-02-28 2020-12-22 Pharming Intellectual Property B.V. Tratamento e prevenção de pré-eclâmpsia
EP3895726A1 (en) * 2020-04-17 2021-10-20 Pharming Intellectual Property BV Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
JP2024525084A (ja) 2021-07-09 2024-07-09 ファーミング・インテレクチュアル・プロパティー・ビー．ブイ． Ｃ１エステラーゼ阻害剤によるウイルス感染関連症状の治療

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601034B1 (fr) 1986-07-03 1989-11-17 Pasteur Institut Inhibiteur de l'activite de la c1-esterase plasmatique (c1-inhibiteur) et d'autres enzymes proteolytiques du groupe des proteases a serine, son procede de preparation, acides nucleiques codant pour cet inhibiteur, methodes de detection d'affections correlees aux defauts dudit inhibiteur a l'aide d'anticorps ou de sondes nucleotidiques et medicaments contenant ledit inhibiteur de synthese
WO1991006650A1 (en) 1989-10-27 1991-05-16 Cetus Corporation C1 inhibitor muteins and uses thereof
WO1992022320A1 (en) * 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor
DE4227762A1 (de) 1992-08-24 1994-03-03 Behringwerke Ag Verwendung eines Kallikrein-Inhibitors zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie bestimmter Krankheiten
US6713662B1 (en) 1994-07-27 2004-03-30 Pharming Intellectual Property B.V. Production of collagen in the milk of transgenic mammals
US7067713B2 (en) * 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
EP1252184B1 (en) * 2000-01-31 2008-01-02 Pharming Intellectual Property B.V. Human c1 inhibitor produced in the milk of transgenic mammals
US7229665B2 (en) * 2001-05-22 2007-06-12 Millipore Corporation Process of forming multilayered structures
US7544853B2 (en) * 2003-05-16 2009-06-09 Pharming Intellectual Property B.V. C1 inhibitor with short half-life transient treatment

Also Published As

Publication number Publication date
CN1791425A (zh) 2006-06-21
US20070185011A1 (en) 2007-08-09
US7544853B2 (en) 2009-06-09
EP1626736B1 (en) 2020-09-16
JP2007500741A (ja) 2007-01-18
ES2830499T3 (es) 2021-06-03
CY1123601T1 (el) 2022-03-24
WO2004100982A1 (en) 2004-11-25
NZ543646A (en) 2009-09-25
AU2004238170B2 (en) 2009-11-05
PT1626736T (pt) 2020-10-13
CN100431604C (zh) 2008-11-12
USRE43691E1 (en) 2012-09-25
PL1626736T3 (pl) 2021-05-04
AU2004238170A1 (en) 2004-11-25
HUE052154T2 (hu) 2021-04-28
CA2525522A1 (en) 2004-11-25
EP1626736A1 (en) 2006-02-22
SI1626736T1 (sl) 2021-04-30

Similar Documents

Publication Publication Date Title
NO2026002I1 (no) Peginterferon beta-1a - forlenget
DK1505963T3 (da) Hepatitis C-inhibitorer
ATE413395T1 (de) N-substituierte pyrazolyl-amidyl-benzimidazolyl-c-kit-inhibitor n
DE602004018837D1 (de) Ptidase-iv-inhibitoren
EP1499336A4 (en) PROTEASE INHIBITORS
ATE333271T1 (de) Uv-stabiles transdermales pflaster
DE60323899D1 (de) Startvorrichtung
DE602004032551D1 (de) Hren dafür
DE602004018746D1 (de) Hren dafür
FI20022276L (fi) Teräsovitelma
PT1626736T (pt) Inibidor c1 com curta meia-vida para tratamento transitório
DE60327447D1 (de) Pflaster
DE602004018936D1 (de) Härtbare zusammensetzung
NO20044269L (no) Smamolekylaere inntrengningsinhibitorer
FI20021531A0 (fi) Muurausmenetelmä
DE602004027413D1 (de) Hren dafür
ATA14732002A (de) Spannvorrichtung
FI20031408A0 (fi) Säilöntälaitteisto
DE60307471D1 (de) Hemmung
NO20022243D0 (no) Fremgangsmåte for rörlegging
DE502004011330D1 (de) Spannvorrichtung
DE50302056D1 (de) Kreuzklemmvorrichtung
FI20040530L (fi) Työkappaleen kiinnitin
DE50302930D1 (de) Startvorrichtung
ITMI20030199A1 (it) Miscele non azeotropiche